Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01118 ...
Drug Name Amiodarone
Molecular Weight 645.3116
Molecular Formula C25H29I2NO3
CAS Number 1951-25-3
SMILES CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
External Links
DRUGBANK DB01118
T3DB T3D4737
PubChem Compound 2157
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 7.2 - 7.2 - https://journals.lww.com/md-journal/fulltext/2018/09140/comedication_with_interacting_drugs_predisposes.46.aspx
Boiling Point 100.0 ℃ 100 ℃ https://auromedics.com/wordpress/wp-content/uploads/Amiodarone-Hydrochloride-Injection-USP-SDS-US-11-28-17.pdf
Melting Point 156.0 ℃ 156 ℃ O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 85. Marly, SA, Belgium.
pKa 6.56 - 6.56±0.06 - https://www.chemicalbook.com/ChemicalProductProperty_US_CB7131332.aspx

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 50.0 % 35-65 % DRUGBANK
Bioavailability 46.0 % 46±22 % PO, oral; adults; patients; The Pharmacological Basis of Therapeutics
C Max 1950.0 ng/ml 1.5-2.4 mcg/ml PO, oral; adults; patients; The Pharmacological Basis of Therapeutics
Css 6195.0 ng/ml 0.4-11.99 ug/ml DRUGBANK
T Max 5.0 h 3-7 h DRUGBANK
T Max 6.0 h 2-10 h PO, oral; adults; patients; The Pharmacological Basis of Therapeutics
Clearance 0.33 L/h/kg 220-440 ml/h/kg intravenous injection, IV; ventricular fibrillation; ventricular tachycardia; DRUGBANK
Clearance 26.1 L/h 0.1-0.77 L/min Total clearance; hepatopathy，LD ↓ ; DRUGBANK
Clearance 0.11 L/h/kg 1.9±0.4 ml/min/kg hydrolysis;  Female, women → ;Elderly → ;RD, renal impairment, Renal disease，including uremia → ;congestive heart disease → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 13.2 L/kg 9.26-17.17 L/kg normal,healthy; DRUGBANK
Volume of Distribution 14.0 L/kg 6.88-21.05 L/kg ventricular tachycardia; patients; DRUGBANK
Volume of Distribution 60.0 L/kg 60.0 L/kg Average volume of distribution; DRUGBANK
Volume of Distribution 66.0 L/kg 66±44 L/kg The Pharmacological Basis of Therapeutics
Half-life 1308.0 h 9-100 day terminal half-life; DRUGBANK
Half-life 1392.0 h 58(15-142) day elimination half-life; DRUGBANK
Half-life 1068.0 h 14-75 day terminal half-life; DRUGBANK
Half-life 41.5 h 3.2-79.7 h elimination half-life; Single dose; DRUGBANK
Half-life 600.0 h 25±12 day PO, oral; at steady state; adults; patients;  Female, women → ;RD, renal impairment, Renal disease，including uremia → ;Age → ; The Pharmacological Basis of Therapeutics
Toxicity LD50 3000.0 mg/kg >3000 mg/kg PO, oral; mouse; Rattus, Rat; DRUGBANK
Toxicity LD50 178.0 mg/kg 178.0 mg/kg intravenous injection, IV; mouse; T3DB
Eliminate Route 0 % 0 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 96.0 % ~96 % DRUGBANK
Protein Binding 100.0 % 99.98±0.01 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1